Skip to main content
SpringerLink
Log in

99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years’ experience

  • Original article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

At all stages of the disease, serious difficulties are encountered in the imaging diagnosis of carcinoids. Somatostatin receptor scintigraphy (SRS) holds great promise for detecting primary tumours and metastases. 99mTc-EDDA/HYNIC-octreotate should significantly improve the diagnosis of carcinoids in comparison with 111In-Octreoscan owing to the better affinity for SSR2 and the higher count rate. The aim of this study was to assess the diagnostic efficiency of 99mTc-EDDA/HYNIC-octreotate scintigraphy in the detection and staging of carcinoid tumours.

Methods

The study population comprised 75 patients (age 48.5±15.5 years): 46 with histological confirmation of carcinoid and 29 with suspected disease. 99mTc-EDDA/HYNIC-octreotate (740 MBq) SRS and CT were performed in all patients. Fifteen patients were examined with 111In-Octreoscan.

Results

High-quality 99mTc-EDDA/HYNIC-octreotate images were obtained in all cases, with maximum tumour tracer accumulation 4 h p.i. The mean target/non-target ratios for whole body (WB) and SPECT scans were, respectively, as follows: primary lesions: 4.5 and 10.2; metastases: liver, 3.1 and 12.3; abdominal focal lesions, 2.7 and 5.8; lung, 2.7 and 8.3; mediastinum, 3.4 and 7.6; bones, 6.8 and 19.0. 99mTc-EDDA/HYNIC-octreotate WB scans revealed more metastases than 111In-Octreoscan, with better individual separation. 99mTc-EDDA/HYNIC-octreotate SRS revealed new metastatic lesions in seven patients with confirmed carcinoid, and in four with dissemination the primary focus was found. Five patients qualified for radioguided surgery and 11 were referred to 90Y-DOTA-TATE therapy. The sensitivity of SRS in comparison with CT was higher for primary lesions and liver and abdominal lymph node metastases. In the subgroup of patients with suspected neuroendocrine tumours, two duodenal carcinoids, one thymic carcinoid and one ileal carcinoid were found.

Conclusion

99mTc-EDDA/HYNIC-octreotate, with high imaging quality, is an excellent alternative to 111In-Octreoscan for staging of carcinoids, and it seems to be the method of choice for detection of the primary focus in patients with metastases from an unknown primary tumour.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20(3):157–98

    Article  PubMed  CAS  Google Scholar 

  2. Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY. Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med 1993;20(4):283–92

    Article  PubMed  CAS  Google Scholar 

  3. Krenning EP, Kwekkeboom DJ, Bakker WA, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe] and [123I-tyr]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20(8):716–31

    Article  PubMed  CAS  Google Scholar 

  4. Blum J, Handmaker H, Lister-James J, Rinne N. A multi-center trial with a somatostatin analog 99mTc depreotide in the evaluation of solitary pulmonary nodules. Chest 2000;177(5):1232–8

    Article  Google Scholar 

  5. Virgolini I, Leimer M, Handmaker H, Lastoria S, Bischof C, Muto P, et al. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829. Cancer Res 1998;58(9):1850–9

    PubMed  CAS  Google Scholar 

  6. Behe M, Maecke HR. New somatostatin analogues labelled with technetium-99m [abstract]. Eur J Nucl Med 1995;22:791

    Google Scholar 

  7. Liu S, Edwards DS, Barrett JA. 99mTc labelling of highly potent small peptides. Bioconjugate Chem 1997;8(5):621–36

    Article  CAS  Google Scholar 

  8. Babich JW, Solomon H, Pike MC, Kroon D, Graham W, Abrams MJ, et al. Technetium-99m-labelled hydrazino nicotinamid derivatized chemotactic peptide analogues for imaging focal sites of bacterial infection. J Nucl Med 1993;34(11):1964–74

    PubMed  CAS  Google Scholar 

  9. Bangard M, Behe M, Guhlke S, Otte R, Bender H, Maecke HR, et al. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In DTPA-D-Phe1-octreotide. Eur J Nucl Med 2000;27(6):628–37

    Article  PubMed  CAS  Google Scholar 

  10. Decristoforo C, Mather JS. Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence. Eur J Nucl Med 1999;26(8):869–76

    Article  PubMed  CAS  Google Scholar 

  11. Decristoforo C, Mather JS, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R. 99mTc EDDA/HYNIC-TOC: a new 99m Tc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med 2000;27(9):1318–25

    Article  PubMed  CAS  Google Scholar 

  12. Płachcińska A, Mikołajczak R, Maecke HR, Młodkowska E, Kunert-Radek J, Michalski A, et al. Clinical usefulness of 99mTc EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a preliminary communication. Eur J Nucl Med Mol Imaging 2003;30(10):1402–6

    Article  PubMed  Google Scholar 

  13. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 for somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27(3):273–82

    Article  PubMed  CAS  Google Scholar 

  14. Kwekkeboom KJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion L, et al. [177Lu-DOTA0,Tyr3] octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 2001;28(9):1319–25

    Article  PubMed  CAS  Google Scholar 

  15. Decristoforo C, Maina T, Nock B, Gabriel M, Cordopatis P, Moncayo R. 99mTc Demotate 1: first data in tumour patients results of a pilot/phase I study. Eur J Nucl Med Mol Imaging 2003;30(9):1211–9

    Article  PubMed  CAS  Google Scholar 

  16. Solcia E, Kloppel G, Sobin LH, et al. Histologic typing of endocrine tumours. WHO International Histological Classification of Tumours. Berlin Heidelberg New York: Springer, 2000

  17. Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, et al. UK NETwork for Neuroendocrine Tumours. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005;54(Suppl 4):iv1–iv16

    Article  PubMed  Google Scholar 

  18. Kuwada SK. Carcinoid tumours. Semin Gastrointest Dis 2000;11(3):157–61

    PubMed  CAS  Google Scholar 

  19. Benjegärd SA, Forssell-Aronsson E, Wängberg B, Skänberg J, Nilsson O, Ahlman H. Intraoperative tumour detection using 111In DTPA-D-Phe-octreotide and scintillation a detector. Eur J Nucl Med 2001;28(10):1456–62

    Article  PubMed  CAS  Google Scholar 

  20. Adams S, Baum RP. Intraoperative use of gamma-detecting probes to localize neuroendocrine tumors. Q J Nucl Med 2000;44(1):59–67

    PubMed  CAS  Google Scholar 

  21. Cholewinski W, Kowalczyk JR, Stefaniak B, Stefaniak J, Poniatowicz-Frasunek E, Tarkowska A. Diagnosis and staging of children’s lymphoma using the technetium-labelled somatostatin analogue, 99mTc-depreotide. Eur J Nucl Med Mol Imaging 2004;31(6):820–4

    Article  PubMed  CAS  Google Scholar 

  22. Shi W, Johnston CF, Buchanan KD, Ferguson WR, Laird JD, Crothers JG, McIlrath EM. Localization of neuroendocrine tumours with [111In]DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. Q J Med 1998;91(4):295–301

    CAS  Google Scholar 

  23. Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 1998;25(10):1396–403

    Article  PubMed  CAS  Google Scholar 

  24. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carcinoid tumour. Lancet 1998;352(9130):799–805

    Article  PubMed  CAS  Google Scholar 

  25. Schillaci O, Spanu A, Scopinaro F, Falchi A, Danieli R, Marongiu P, et al. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2003;44(3):359–68

    PubMed  CAS  Google Scholar 

  26. Soga J. Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases. Cancer 2005;15:103(8):1587–595

    Article  Google Scholar 

  27. Vinik A. Carcinoid tumors. http://www.endotext.com/guthormones/guthormone2/guthormoneframe2.htm

  28. Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. Oncologist 2005;10(2):123–31

    Article  PubMed  Google Scholar 

  29. Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, Bartolomei M. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001;28(4):426–34

    Article  PubMed  CAS  Google Scholar 

  30. Fueger BJ, Hamilton G, Raderer M, Pangerl T, Traub T, Angelberger P, et al. Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells. J Nucl Med 2001;42(12):1856–62

    PubMed  CAS  Google Scholar 

  31. Amthauer H, Ruf J, Bohmig M, Lopez-Hanninen E, Rohlfing T, Wernecke KD, et al. Diagnosis of neuroendocrine tumours by retrospective image fusion: is there a benefit? Eur J Nucl Med Mol Imaging 2004;31(3):342–8

    Article  PubMed  CAS  Google Scholar 

  32. Hofmann M, Maecke H, Börner AR, Weckesser E, Schöffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28(12):1751–7

    Article  PubMed  CAS  Google Scholar 

  33. Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe1-Tyr3-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5(1):42–8

    Article  PubMed  Google Scholar 

  34. Öberg K, Eriksson B. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab 2005;19(2):265–76

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was performed within COST B12, WG3 “Radiolabelled peptides for receptor imaging”.

Author information

Authors and Affiliations

  1. Nuclear Medicine Unit, Department of Endocrinology, Medical College, Jagiellonian University, Cracow, Poland

    A. Hubalewska-Dydejczyk, K. Fröss-Baron, B. Huszno, D. Pach & A. Sowa-Staszczak

  2. Gastrointestinal and General Surgery Department, Medical College, Jagiellonian University, Cracow, Poland

    P. Szybiński & J. Kulig

  3. Radioisotope Centre POLATOM, Otwock-Swierk, Poland

    R. Mikołajczak & B. Janota

  4. Radiological Chemistry Unit, University Hospital, Basel, Switzerland

    H. R. Maecke

Authors
  1. A. Hubalewska-Dydejczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Fröss-Baron
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Mikołajczak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. R. Maecke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Huszno
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Pach
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Sowa-Staszczak
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B. Janota
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P. Szybiński
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J. Kulig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Hubalewska-Dydejczyk.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hubalewska-Dydejczyk, A., Fröss-Baron, K., Mikołajczak, R. et al. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years’ experience. Eur J Nucl Med Mol Imaging 33, 1123–1133 (2006). https://doi.org/10.1007/s00259-006-0113-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-006-0113-7

Keywords

Search

Navigation